The Brazilian real estate fund (FII) HREC11 is set to receive R$ 117.3 million from the Thera CRI on November 9. At the same time, it has already allocated R$ 60.8 million into a new CRI issuance—the HRCO—yielding IPCA+9.20% per year. This portfolio recycling, formalized in a material fact filing, marks the fund's largest asset reallocation since its IPO. Two assets acquired at IPCA+5.38% and IPCA+6.25% are giving way to operations aligned with current market conditions. The distribution reflects this shift, having climbed 25% since April to reach R$ 0.10 per unit in October—a jump that our previous analysis had not captured.
Did HREC11 issue new units in November 2026?
Not of units. This material fact filing does not launch a public offering; there are no new units for sale and no primary issuance price for unitholders to evaluate. Instead, the manager used fund cash to acquire the HRCO CRI, a new issuance of real estate receivables certificates (119th and 120th series issuances) yielding IPCA+9.20% per year. The distinction matters: in a unit offering, unitholders decide whether to put in more capital, whereas in a CRI acquisition, the manager uses existing fund cash to swap one asset for another. Unitholders do not pay anything out of pocket, but the monthly distribution and portfolio risk profile change.
The filing formalizes three simultaneous moves by HREC11:
| Asset | Rate | Status in November | Total Volume |
|---|---|---|---|
| Thera CRI | IPCA+6.25% | Early redemption underway — R$ 117.3 million arriving on Nov 9; balance of ~R$ 49.9 million by Jan 21, 2027 | ~R$ 168 million |
| Sol Panamby CRI | IPCA+5.38% | 1st tranche settled (R$ 15 million on Oct 23); R$ 31.9 million pending with an 18-month maximum term | ~R$ 47 million |
| HRCO CRI (new) | IPCA+9.20% | Already allocated — 13.1% of net asset value; backed by properties in the Hedge ecosystem; matures Oct 2033 | R$ 60.8 million |
The Thera CRI was backed by 10 units in the Thera Corporate building in São Paulo. The HRCO CRI, which partially replaces it, is backed by the final purchase installments for the Thera Corporate and Morumbi 8.200 buildings—two properties within the same Hedge ecosystem, now financing different buyers. The yield increases by 2.95 percentage points in the transition from one to the other.
What is the value of this rate difference—from IPCA+6% to IPCA+9.20%?
A difference of 2.95 percentage points may look small in a headline, but on the fund's balance sheet, it makes a meaningful impact. The Thera CRI alone accounted for roughly 36% of the fund's net asset value (NAV) of R$ 463.4 million. At R$ 168 million yielding IPCA+6.25%, that asset's real annual cash contribution was about R$ 10.5 million (excluding the inflation adjustment). If that same capital is fully recycled at IPCA+9.20%, the contribution rises to R$ 15.5 million—an annual gain of R$ 5 million, or R$ 417,000 per month.
With approximately 51 million units outstanding (our estimate based on NAV of R$ 463.4 million divided by a book value of R$ 9.07), this equates to roughly R$ 0.008 per unit per month in incremental income for every R$ 168 million batch fully recycled. The HRCO captures only the first slice of R$ 60.8 million, while the remainder awaits reallocation. The total impact depends on the timing and rates of the upcoming allocations.
+2.95 percentage points versus Thera and +3.82 percentage points versus Sol Panamby, reflecting current CRI market conditions
Was ~8% in our last published analysis—nearly double, with R$ 73.7 million in repurchase agreements (compromissadas)
Unit price at R$ 8.28; book value at R$ 9.07—a 9% discount that the previous analysis did not capture (it stood at 0.97)
Why did HREC11's distribution rise 25%, and when did it start?
Our previous analysis stated that HREC11 was paying R$ 0.08 per unit monthly, which had been stable for seven months. That was true through March 2026. In April, the distribution jumped to R$ 0.095, where it stayed for six consecutive months before rising again to R$ 0.10 in October. This shift was missed by the prior analysis, which relied on February data.
The current market price of R$ 8.28 brings the annualized dividend yield to 14.5% (R$ 0.10 × 12 / R$ 8.28), well above the 13.3% cited in the previous analysis, which used R$ 0.08 as the baseline distribution. Even using the more conservative average of R$ 0.095, the dividend yield reaches 13.8%. For unitholders, the payout grew without a proportional increase in the unit price. The price-to-book ratio shifted from 0.97 to 0.91, which reopens some room for capital gains should the unit price move back toward book value.
Book value itself has recovered, moving from R$ 8.90 in March 2026 to R$ 9.07 currently—a 1.9% gain over eight months. Part of this improvement stemmed directly from the Thera CRI. Because the asset was marked at a market rate higher than its issuance rate (6.25%), the early redemption at curve value generated a positive effect on the fund's book value per unit, as described in the material fact filing.
Why has leverage doubled to 15.91%, and when will it fall?
The risk that has grown the most since our last analysis is not found in defaulting CRIs, as the fund maintains 100% compliance. Instead, it is leverage. At the end of October 2026, indebtedness via repurchase agreements reached 15.91% of net asset value, equivalent to approximately R$ 73.7 million (our estimate: 15.91% × R$ 463.4 million). In our previous analysis, leverage stood at roughly 8% of NAV.
The manager's explanation is coherent: it made early acquisitions—the HRCO CRI itself and potentially others—before receiving the amortizations from the Thera and Sol Panamby CRIs, using leverage as a bridge. The logic is defensible, as buying at IPCA+9.20% before receiving the Thera proceeds avoids leaving capital idle. The risk is that while this leverage remains unhedged or unclosed, it increases the fund's cost during any liquidity stress. With R$ 117.3 million arriving on November 9, a substantial portion of this debt can be paid off immediately. The incoming amount exceeds current leverage, leaving enough capital to clear all debt and still have funds left over for new allocations. A similar situation occurred in a sister fund managed by Hedge in October, where indebtedness reached 24.2% before being partially reduced.
The risk concentrated in the five IZP CRIs (Design Offices, ~28% of NAV) remains unchanged by this document: partially completed physical construction, high loan-to-value ratios, and intra-group borrowing. There is nothing new here, but no improvement either.
The distribution you receive has risen from R$ 0.08 to R$ 0.10 since April—in your account, that change has already taken place. What changes now is the execution timeline. In November, the manager receives ~R$ 117 million and must decide where to allocate it. If CRI market rates hold around IPCA+9%, the remaining ~R$ 108 million (the portion not allocated to HRCO) will flow into higher-yielding CRIs than the ones they replace, which supports or raises the distribution. If leverage drops concurrently, operational risk shrinks. The current dividend yield of ~14.5% at R$ 8.28 represents a solid premium over equivalent Treasury IPCA+ bonds. Our previous analysis estimated this spread at around 380 basis points, and the 9% discount on the P/BV suggests that this premium has widened. Unitholders should monitor where the November cash goes and whether Sol Panamby pays on schedule.
The remaining balance of the Sol Panamby CRI: real risk or just timing?
The Sol Panamby CRI had two distinct collateral pools: Shopping Jaraguá (in Araraquara) and Grupo SolPanamby. The first tranche, tied to Shopping Jaraguá, was settled on October 23 for R$ 15 million, including a 2% penalty. However, the remaining balance of R$ 31.9 million owed directly by Grupo SolPanamby has an 18-month maximum term, with maturity extending up to April 9, 2028. The manager states it expects settlement ahead of schedule, but no guarantees were detailed in the filing.
This R$ 31.9 million accounts for roughly 6.9% of the fund's NAV. Until it is paid off, the asset weighs on the portfolio at a rate of IPCA+5.38%, the lowest in the portfolio. The document does not disclose penalty interest terms or additional guarantees from Grupo SolPanamby. Other Hedge funds have faced prolonged liquidation processes. HREC11 has a contract with a defined timeline, which is different, but investors should mark October 2027 on their calendars, when half of that term will have elapsed without an update.
Destination of the R$ 117.3 million from Thera (starting Nov 9) — What will the manager do with this cash? Pay down the ~R$ 73.7 million in leverage, allocate to new CRIs at current rates, or both. The November managerial report (expected in December) is where these accounts balance out. Trigger: new allocations above IPCA+9% will sustain the distribution; leverage below 8% will confirm that the manager prioritized the balance sheet.
Leverage post-Thera — With R$ 117.3 million coming in, the fund can clear its entire ~R$ 73.7 million in leverage and still have ~R$ 43 million left over. If the next report shows leverage above 10%, it means the manager reallocated part of the cash before paying off the debt. This is not necessarily wrong—it depends on the borrowing rate versus liability costs—but leverage above 15% again would be a warning sign.
Sol Panamby (R$ 31.9 million through Apr 2028) — The fund did not disclose penalty terms or additional guarantees from Grupo SolPanamby. If the deadline passes without payment, collateral enforcement could occur. Checkpoint: the Q2 2027 managerial report, by which time half the term will have passed without an announcement.
For those tracking Hedge Investments' track record across other funds in its ecosystem, this material fact filing leans more positive than its recent average. Low-yielding assets are leaving, and exposure to better rates is entering. The risk concentrated in the IZP CRIs remains, and the temporary spike in leverage was the price paid to execute the portfolio swap quickly. If the November cash is allocated effectively, our complete analysis of the HREC11 real estate fund will have an improved chapter to tell.
